[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trigeminal-neuralgia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trigeminal-neuralgia":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,44,67,114,138,165,191,214,237,259,283,300,323,363,388,407,428,451,478,501,524,548,574,599,622],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":28,"conditions":29,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643801","phase-1-rp-008-in-combination-with-daily-oral-varenicline-for-the-treatment-of-trigeminal-neuralgia-100643801",false,"NCT07596485","RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia","A Phase 1\u002F2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, and PRELIminary EFficacy of Percutaneous Injection of RP-008 Followed by Daily Oral Varenicline in Patients With Trigeminal Neuralgia (The RELIEF Study)","RELIEF","Inclusion Criteria:\n\n* Participant is capable of providing signed informed consent.\n* Participant must be between 18 to 80 years of age (inclusive), at the time of signing the informed consent.\n* Confirmed diagnosis of classical or idiopathic TN according to the criteria of the International Classification of Headache Disorders-3rd edition (ICHD-3, 2018).\n* The diagnosis of TN established at least 6 months prior to Screening.\n* Participant has purely unilateral pain attacks limited primarily to the maxillary (V2) and\u002For mandibular (V3) division of the trigeminal nerve.\n* Participant has failed at least 1 standard of care anti-epileptic agent (e.g., carbamazepine, oxcarbazepine, pregabalin, gabapentin, phenytoin, lamotrigine). Failure to a prior anti-epileptic medication is defined as insufficient pain relief despite use of a therapeutic dose for an adequate duration of time or being unsuitable due to contraindications or intolerance to side effects.\n* Participant is on stable dosage of any TN anti-epileptic agent(s) for a minimum of 6 weeks prior to Screening.\n\nExclusion Criteria:\n\n* Participant has bilateral TN pain attacks.\n* Participants with secondary TN, defined by ICHD-3 as TN caused by an underlying disease (e.g., tumor in the cerebellopontine angle, arteriovenous malformation, or multiple sclerosis).\n* Participants with facial pain not meeting the ICHD-3 diagnostic criteria for either classical or idiopathic TN, including: trigeminal autonomic cephalalgias, cluster headache, hemicrania continua, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA).\n* Participants who had no change in pain after taking sodium channel blockers despite the use of a therapeutic dose for an adequate duration of time.","ALL","18 Years","80 Years",{"count":22,"type":23},24,"ESTIMATED","INTERVENTIONAL",[26,27],"PHASE1","PHASE2","The goal of this study is to evaluate if KRIYA-748 (RP-008) is safe, tolerable, and preliminary effective in treating trigeminal neuralgia (TN) when used in combination with varenicline tartrate. The study will also assess what doses of RP-008 are safe and tolerable for participants and how the severity of participants' TN pain and frequency of facial pain attacks are affected.",[30],"Trigeminal Neuralgia","RECRUITING","2026-06-04",{"date":34,"type":35},"2026-06-08","ACTUAL",{"date":37,"type":23},"2026-08",{"date":39,"type":23},"2029-02",{"name":41,"class":42},"Kriya Therapeutics, Inc.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100637616","high-intensity-laser-therapy-versus-low-level-laser-therapy-in-the-treatment-of-trigeminal-neuralgia-100637616","NCT07590414","High-intensity Laser Therapy Versus Low Level Laser Therapy in the Treatment of Trigeminal Neuralgia","High-intensity Laser Therapy Versus Low Level Laser Therapy in the Treatment of Trigeminal Neuralgia (a Randomized Clinical Trial)","Inclusion Criteria:\n\n* Patients diagnosed with trigeminal neuralgia according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria.\n* Patients with drug refractory trigeminal neuralgia (defined as poor response to adequate pharmacological treatment or intolerance to side effects for at least three months).\n* Patients who are contraindicated for surgical intervention or any other interventions, or who have previously undergone such interventions without obtaining satisfactory pain relief.\n\nExclusion Criteria:\n\n* patients with secondary trigeminal neuralgia diagnosed with brain lesions that is indicated for surgery (percutaneous procedures, gamma knife, microvascular decompression).\n* Patients with other orofacial conditions such as temporomandibular disorders, migraine, or other neurological diseases.\n* Patients with contraindications to laser use (e.g., pacemakers).\n* Patients who are responding well to medical treatment.\n* Pregnant or lactating women.",{"count":52,"type":23},38,[54],"NA","Trigeminal neuralgia (TN) is the most common and severe type of neuropathic pain disorder affecting the orofacial region. It is characterized by sudden, intense, episodic attacks of pain in the distribution of trigeminal nerve, usually unilateral. The condition severely impairs patient's quality of life. TN represents a diagnostic and therapeutic challenge, pharmacological therapy remains the first-line management, and many patients experience reduced drug tolerance or significant side effects over time. Surgical options are considered for refractory cases but are invasive and carry risks such as infection, nerve damage, and recurrence of symptoms. In recent years, laser based therapies have gained attention as safe, non-invasive alternatives. Low level laser therapy (LLLT) promotes photo-biomodulation and nerve repair without thermal damage, while high-intensity laser therapy (HILT) can achieve deeper penetration and direct neuromodulation. However, comparative evidence regarding their efficacy in TN is still limited. Aim: The present study aims to evaluate and compare the effect of High intensity laser therapy and low level laser therapy in reducing pain intensity and improving quality of life in patients with trigeminal neuralgia.",[30],"NOT_YET_RECRUITING","2026-05-10",{"date":60,"type":35},"2026-05-15",{"date":60,"type":23},{"date":63,"type":23},"2026-12-30",{"name":65,"class":66},"Alexandria University","OTHER",{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":102,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100571728","neurosurgical-outcome-network-100571728","NCT06724029","Neurosurgical Outcome Network","Neurosurgical Outcome Network Per la Predizione Dell'Outcome in Neurochirurgia","NEON","Inclusion Criteria:\n\n* Neuro-oncological pathology: supratentorial and subtentorial tumors, intra and extra axial tumors excluding the skull base (anterior, middle and posterior fossa; sellar and parasellar region)\n* Basicranial pathology: tumors originating from the anterior cranial fossa, middle cranial fossa and posterior cranial fossa, sellar region with or without supratentorial\u002Fparasellar development.\n* Vascular pathology: aneurysms, AVMs, cavernomas, other pathologies (Moyamoya disease, dural fistulas, nontraumatic hematomas)\n* Traumatic pathology: diffuse damage (nonvisible diffuse damage, diffuse damage, diffuse damage with edema, diffuse damage with shift) and focal damage (acute\u002Fsubacute\u002Fchronic subdural hematoma, extradural hematoma, subarachnoid hemorrhage, intraparenchymal hematoma, fractures); hydrocephalus. The inclusion criterion for chronic subdural hematoma is recent bleeding for TBI with CT finding of chronic subdural hematoma candidate for evacuation surgery.\n* Spinal pathology: degenerative cervical (anterior\u002Fposterior), myelopathic, and trauma pathology; instrumented, uninstrumented thoracolumbar pathology (disc pathology, canal pathology), and trauma pathology; oncologic spinal pathology.\n* Functional pathology: Parkinson's disease, spasticity, trigeminal neuralgia, craniofacial pain\u002Falgia, neuropathic pain, tremor, dystonias, obsessive compulsive disorder, drug-resistant epilepsies, depression. Normotensive hydrocephalus.\n* Peripheral nervous system pathology: peripheral nerve compression syndromes, peripheral nerve and plexus tumors, brachial plexus and peripheral nerve trauma (contusion and section)\n* Malformative pathology: Chiari malformation type 1 and craniostenoses including both those framed in malformative syndromes and those not framed in malformative syndromes (monosutural craniostenoses: trigonocephaly, plagiocephaly, scaphocephaly; multisutural craniostenoses). Malformative hydrocephalus.\n* For cognitive and psychological assessment: age 18 years or older; adequate understanding of Italian language; diagnosis of glioma, meningioma, vascular pathology, spinal pathology\n\nExclusion Criteria:\n\n* For cognitive and psychological assessment: patients with psychiatric diseases in history and\u002For taking psychotropic drugs; presence of overt cognitive decline (not due to the injury) in history; patients younger than 18 years old.",{"count":76,"type":23},4500,"OBSERVATIONAL","The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to assess outcomes and their predictors using measures agreed upon by the participating centers. Standardizing the evaluation of outcomes and predictors improves the quality of research, allows for data comparison, and facilitates a \"common language\" in routine clinical practice. Most importantly, it influences therapeutic decisions in various neurosurgical conditions. Clinically, the identified predictors can also be used during preoperative assessments to provide more precise guidance to patients undergoing surgery.",[80,81,82,83,84,85,86,87,88,89,90,91,30,92,93,94,95,96,97,98,99,100,101],"Aneurysms","Arteriovenous Malformations","Cavernomas","Skull Base Tumors","Moyamoya Disease","Dural Fistulas","Subdural Hematoma","Extradural Hematoma","Subarachnoid Hemorrhage","Hydrocephalus","Parkinson&Amp;#39;s Disease","Spasticity","Craniofacial Pain","Neuropathic Pain","Tremor","Dystonias","Obsessive-compulsive Disorder","Drug-resistant Epilepsy","Depression","Normal Pressure Hydrocephalus","Tumors of Peripheral Nerves","Chiari Malformation Type 1",[103],"Neurosurgery Outcome Artificial Intelligence predictors","2026-03-25",{"date":106,"type":35},"2026-03-30",{"date":108,"type":35},"2022-12-05",{"date":110,"type":23},"2027-06",{"name":112,"class":66},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",27,{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":121,"targetDuration":4,"studyType":24,"phases":123,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100591246","the-alternative-effects-of-electroacupuncture-in-the-treatment-of-trigeminal-neuralgia-100591246","NCT06977932","The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia","The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia: Protocol for a Multicentre Randomised Controlled Trial","Diagnostic Criteria\n\nDiagnosis was based on the criteria for trigeminal neuralgia (TN) as defined in the third edition of the International Classification of Headache Disorders (ICHD-3) published by the International Headache Society (IHS) in 2018. The diagnostic criteria included:\n\n1. recurrent unilateral facial pain occurring in the distribution of one or more divisions of the trigeminal nerve, without radiation outside the trigeminal territory, and meeting criteria (2) and (3);\n2. pain presenting with all of the following characteristics:\n\n   ① paroxysmal attacks lasting from a few seconds to 2 minutes;\n\n   ② severe intensity;\n   * electric shock-like, stabbing, or sharp quality;\n3. pain triggered by innocuous stimuli within the affected trigeminal distribution;\n4. exclusion of other facial pain disorders classified in ICHD-3.\n\n   Inclusion Criteria\n\n   All of the following criteria had to be met for study enrollment:\n   * fulfillment of the TN diagnostic criteria as stated above;\n\n     * age between 18 and 80 years, inclusive, irrespective of sex;\n\n       * receiving a stable daily dose of carbamazepine (200-400 mg); ④ consciousness clear, with intact pain perception and discrimination, and able to communicate effectively; ⑤ voluntary participation with written informed consent provided by the patient or their legal guardian\u002Fauthorized representative.\n\n   Exclusion Criteria\n\n   Participants were excluded if they met any of the following:\n   * comorbid epilepsy, head injury, or other relevant neurological disorders;\n\n     * significant impairment of cardiac, hepatic, or renal function;\n\n       * cognitive dysfunction, aphasia, psychiatric conditions, or inability to cooperate with treatment;\n\n         * poorly controlled hypertension or hyperglycemia;\n\n           ⑤ recent diagnosis of severe anxiety or depression;\n\n           ⑥ pregnancy or lactation;\n\n           ⑦ presence of a cardiac pacemaker or other contraindications to electroacupuncture therapy;\n\n           ⑧ current participation in another clinical trial.",{"count":122,"type":23},126,[54],"Trigeminal neuralgia (TN), characterized by its refractory nature and recurrence, frequently leads to anxiety, depression, and insomnia, thereby significantly diminishing patients' quality of life and potentially inducing self-harm. Carbamazepine (CBZ) is the first-line medication for TN, yet it presents adverse effects such as addiction and the absence of analgesic effects upon cessation. Acupuncture, particularly electroacupuncture（EA）, has demonstrated efficacy in TN treatment, although its therapeutic outcomes are influenced by various factors. Consequently, this study aims to evaluate the clinical efficacy of EA for TN and its potential as an alternative to CBZ treatment.",[30],[127,128],"Electroacupuncture","Randomized Controlled Trial","2026-03-02",{"date":131,"type":35},"2026-03-05",{"date":133,"type":23},"2026-03-01",{"date":135,"type":23},"2028-12-31",{"name":137,"class":66},"Yuanyuan Wu",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":146,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":43},"100278898","the-will-erwin-headache-research-center---cluster-headache-study-100278898","NCT02910323","The Will Erwin Headache Research Center - Cluster Headache Study","The Will Erwin Headache Research Center Study of Cluster Headache and Trigeminal Neuralgia","WEC1","Inclusion Criteria:\n\n* Diagnosis of a trigeminal autonomic cephalalgia according to the International Headache Classification including episodic cluster headache, chronic cluster headache, episodic paroxysmal hemicrania, chronic paroxysmal hemicrania, episodic short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), chronic SUNCT, episodic short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA), chronic SUNA, and hemicrania continua. OR Diagnosis of a trigeminal neuralgia according to the International Headache Classification, including classical trigeminal neuralgia and symptomatic trigeminal neuralgia.\n* Able to provide HIPAA authorization to share prior medical records\u002Fimaging.\n\nExclusion Criteria:\n\n* Life expectancy less than 1 year, co-existing disease or other characteristic that precludes appropriate diagnosis of a trigeminal autonomic cephalalgia or trigeminal neuralgia.\n* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements\n* Inability or unwillingness of subject or legal guardian\u002Frepresentative to give informed consent.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Inclusion criteria is willingness to consent and be of age 18 and older",true,{"count":148,"type":23},1500,"The Will Erwin Headache Research Center Study of Cluster Headache and Trigeminal Neuralgia is a prospective, multicenter, observational research network for subjects with Cluster Headache and\u002For Trigeminal Neuralgia.",[151,152,153,154,155,30],"Cluster Headache","Cluster Headaches and Other Trigeminal Autonomic Cephalgias","Paroxysmal Hemicrania","SUNCT","Hemicrania Continua","2026-02-13",{"date":158,"type":35},"2026-02-18",{"date":160,"type":4},"2016-07-12",{"date":162,"type":23},"2035-12",{"name":164,"class":66},"The University of Texas Health Science Center, Houston",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":174,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":43},"100532751","phase-4-onabotulinumtoxina-for-trigeminal-neuralgia-100532751","NCT06216886","OnabotulinumtoxinA for Trigeminal Neuralgia","Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.","Inclusion Criteria:\n\nMen and women age 18 or older\n\n* Judged to be of legal competence\n* Sufficient knowledge of written and spoken English\n* Capable of attending regular in-person visits\n* Have failed\u002Fnot a candidate\u002Fdo not want surgery\n* Inadequate response to medication - at least 2 trials\n* Meeting ICHD criteria for Classical Trigeminal Neuralgia 13.1.1.1\n* Patients with frequency \\> 10 attacks per week\n* Stable dose of medications in the last 2 weeks\n\nExclusion Criteria:\n\n* Secondary or Idiopathic TN, or Painful Trigeminal Neuropathy as defined by the ICHD (13.1.1.2, 13.1.1.3, 13.1.2)\n* Pregnant or breast feeding (while it is rare that a patient will be pregnant with TN, there is not sufficient data to say definitively that onabotA is ok to use during pregnancy and nursing, it is still rated Class C)\n* Neuromuscular disease\n* On aminoglyocosides\n* Not currently enrolled in any other studies",{"count":173,"type":23},20,[175],"PHASE4","A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.",[30],[179,180,181],"botox","injection","trigeminal neuralgia","2026-01-20",{"date":184,"type":35},"2026-01-22",{"date":186,"type":35},"2024-06-01",{"date":188,"type":23},"2027-09-01",{"name":190,"class":66},"Stanford University",{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":24,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100620392","resting-state-fmri-study-of-functional-connectivity-after-gamma-knife-radiosurgery-in-trigeminal-neuralgia-100620392","NCT07357025","Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia","Longitudinal Resting-State fMRI Assessment of Brain Functional Connectivity in Patients With Trigeminal Neuralgia Treated by Gamma Knife Radiosurgery","DOCTRINE","Inclusion Criteria:\n\n* Adults aged 18 to 73 years\n* Diagnosis of classical trigeminal neuralgia confirmed by an experienced neurologist\n* Unilateral facial pain with a normal neurological examination\n* Pharmacoresistant trigeminal neuralgia, defined as failure of at least two appropriate medical treatments, intolerance to medication, or recurrence despite adequate treatment\n* Indication for Gamma Knife radiosurgery as part of standard clinical care\n* Affiliation to a social security or health insurance system\n* Ability to understand the study information and provide written informed consent\n\nExclusion Criteria:\n\n* Diagnostic uncertainty or secondary\u002Fidiopathic trigeminal neuralgia\n* Previous surgical or radiosurgical treatment for trigeminal neuralgia\n* Participation in another interventional clinical study at the time of inclusion\n* Individuals belonging to protected populations as defined by applicable regulations (including minors, adults under legal protection, persons deprived of liberty, pregnant or breastfeeding women)\n* Inability to understand the French language\n* Contraindication to 3 Tesla MRI, including claustrophobia, presence of pacemaker, defibrillator, metallic prosthesis, or any MRI-incompatible device or foreign body\n* Residence distance incompatible with the required follow-up schedule","73 Years",{"count":201,"type":23},28,[54],"Trigeminal neuralgia is a severe chronic pain condition with a major impact on quality of life. Although Gamma Knife radiosurgery is an established treatment for pharmacoresistant trigeminal neuralgia, its mechanisms of action and the temporal dynamics of clinical response remain incompletely understood.\n\nThis prospective longitudinal study aims to investigate changes in brain functional connectivity using resting-state functional magnetic resonance imaging (rs-fMRI) in patients with classical trigeminal neuralgia treated with Gamma Knife radiosurgery. Participants will undergo rs-fMRI examinations before treatment and at 1 month, 3 months, and 12 months after radiosurgery.\n\nFunctional connectivity patterns will be analyzed over time and correlated with clinical outcomes, including pain intensity and treatment response. Imaging data will be compared with those from a cohort of age- and sex-matched healthy volunteers. The study does not modify standard clinical care; only additional non-invasive MRI examinations without contrast injection are performed for research purposes.",[30],"2026-01-15",{"date":207,"type":35},"2026-01-21",{"date":209,"type":23},"2026-04-01",{"date":211,"type":23},"2029-04-01",{"name":213,"class":66},"Assistance Publique Hopitaux De Marseille",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":24,"phases":223,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100614102","efficacy-and-safety-of-irregular-pulsed-radiofrequency-sluijter-teixera-poisson-versus-regular-pulsed-radiofrequency-to-the-gasserian-ganglion-for-treatment-of-primary-trigeminal-neuralgia-100614102","NCT07275229","Efficacy and Safety of Irregular Pulsed Radiofrequency (Sluijter-Teixera Poisson) Versus Regular Pulsed Radiofrequency to the Gasserian Ganglion for Treatment of Primary Trigeminal Neuralgia","Inclusion Criteria:\n\n* Clinical diagnosis of primary trigeminal neuralgia according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)\n* Age between 18 and 75 years\n* Severe trigeminal neuralgia not adequately relieved by conservative medical therapy, including carbamazepine or oxcarbazepine\n* Numeric Rating Scale (NRS-11) pain score of 7 or higher prior to the procedure\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Secondary trigeminal neuralgia, including trigeminal neuralgia attributed to space-occupying lesions or multiple sclerosis\n* Infection at the puncture site\n* History of psychiatric disease\n* Clinically significant abnormalities in routine laboratory tests, including hepatic, renal, or coagulation function, or abnormalities on electrocardiogram or chest X-ray\n* Serious systemic diseases, including uncontrolled hypertension or diabetes mellitus, or cardiac dysfunction classified as New York Heart Association class II-III\n* History of narcotic substance abuse\n* Previous treatment with continuous radiofrequency to the gasserian ganglion or peripheral branches, glycerol rhizolysis, balloon compression, gamma knife surgery, or other neuroablative procedures\n* Previous microvascular decompression","75 Years",{"count":222,"type":23},62,[54],"This study aims to compare between the Efficacy and safety of irregular pulsed radiofrequency STP versus regular pulsed radiofrequency to the gasserian ganglion for treatment of primary trigeminal neuralgia.",[30],[227],"radiofreqency for treatment of trigeminal neuralgia","2025-12-24",{"date":230,"type":35},"2025-12-31",{"date":232,"type":23},"2025-12",{"date":234,"type":23},"2027-04",{"name":236,"class":66},"Sohag University",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":146,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":24,"phases":245,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":43},"100495968","early-phase-1-trigeminal-evoked-responses-to-improve-rhizotomy-100495968","NCT05738096","Trigeminal Evoked Responses to Improve Rhizotomy","Inclusion Criteria:\n\n* Adults of 18 years or older\n* Scheduled to undergo percutaneous rhizotomy for facial pain\n\nExclusion Criteria:\n\n* For TGN: Facial pain of unclear origin (i.e. not clearly TGN pain) or Rhizotomy procedure canceled\n* For Healthy control: Diagnosis or history of facial pain such as TMD or TGN, History of migraine, History of any functional pain disorder: fibromyalgia, IBS, CRPS or Recent chronic pain (within last month)",{"count":244,"type":23},30,[246],"EARLY_PHASE1","Trigeminal neuralgia (TGN) is a debilitating pain syndrome where electrical, shock- like jolts of pain affect the face. Trigeminal somatosensory evoked potentials (TSEPs) provide a promising modality for measuring the trigeminal sensory and nociceptive pathway by using peripheral stimulation of the trigeminal nerve (on the skin) and measuring low latency evoked potentials on the scalp (contralateral sensory cortex). While TSEPs have been measured in the past, it is not clear if implementing TSEPs into a routine neurosurgical rhizotomy procedure will be feasible. This is a prospective cohort study examining the feasibility of routinely performing TSEPs during rhizotomies for TGN.",[30,249],"Rhizotomy","2025-11-24",{"date":252,"type":35},"2025-11-26",{"date":254,"type":35},"2023-11-01",{"date":256,"type":23},"2026-11-01",{"name":258,"class":66},"University of Minnesota",{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":4},"100611258","risk-factors-for-recurrence-of-trigeminal-neuralgia-after-percutaneous-balloon-compression-100611258","NCT07238244","Risk Factors for Recurrence of Trigeminal Neuralgia After Percutaneous Balloon Compression","Development and Validation of a Machine Learning-Based Risk Prediction Model for Recurrence After Percutaneous Balloon Compression in Trigeminal Neuralgia Patients: A Retrospective Cohort Study","Inclusion Criteria:\n\n1. Aged ≥ 18 years.\n2. Meet the diagnostic criteria for primary trigeminal neuralgia according to the International Classification of Headache Disorders, 3rd edition (ICHD-3).\n3. Undergo the first PBC treatment.\n4. Have complete preoperative clinical data, imaging data, and intraoperative records.\n5. Have at least one postoperative follow-up record available for determining the recurrence status.\n\nExclusion Criteria:\n\n1. Secondary trigeminal neuralgia (e.g., caused by cerebellopontine angle tumors, multiple sclerosis, etc.).\n2. Missing rate of key predictor variables (e.g., balloon shape) or outcome variables \\> 15%.\n3. Postoperative loss to follow-up (defined as no follow-up records available).",{"count":267,"type":23},700,"The goal of this observational study is to develop and validate a machine learning-based model for predicting pain recurrence risk after percutaneous balloon compression (PBC) in adult patients with primary trigeminal neuralgia (TN) who had their first PBC treatment. The main questions it aims to answer are:\n\nCan the machine learning-based model accurately predict pain recurrence after PBC in these primary TN patients? What key factors (like patient baseline traits, imaging parameters, surgical operation data) affect PBC post-operative pain recurrence? Do machine learning algorithms perform better than traditional Cox proportional hazards regression in predicting such recurrence? Participants (with existing PBC treatment records) will have their past data-including clinical info from the hospital's electronic medical record system, imaging data from the image archiving system, surgical data from the surgical anesthesia system, and follow-up data from the outpatient system-collected and analyzed to build and validate the prediction model.",[30],[30,271,272,273],"Percutaneous Balloon Compression","predication","Machine Learning Model","2025-11-17",{"date":276,"type":35},"2025-11-20",{"date":278,"type":23},"2025-12-15",{"date":280,"type":23},"2026-03-15",{"name":282,"class":66},"Second Xiangya Hospital of Central South University",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":241,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":146,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":290,"conditions":291,"keywords":292,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":43},"100459965","trigeminal-neuralgia-electrophysiology-100459965","NCT05269472","Trigeminal Neuralgia Electrophysiology","Inclusion Criteria (TGN):\n\n* Adults of 18 years or older\n* Scheduled to undergo percutaneous rhizotomy for facial pain\n\nExclusion Criteria (TGN):\n\n* Facial pain of unclear origin (i.e. not clearly TGN pain)\n* Rhizotomy procedure canceled\n\nInclusion Criteria (Healthy controls)\n\n* Adults of 18 years or older\n\nExclusion Criteria (Healthy Controls)\n\n* Diagnosis or history of facial pain such as TMD or TGN\n* History of migraine\n* History of any functional pain disorder: fibromyalgia, IBS, CRPS\n* Recent chronic pain (within last month)\n* Unwilling to participate for two hours in lab\n* Current acute pain",{"count":244,"type":23},"The study intervention is to perform standard somatosensory evoked responses limited to the face during rhizotomy procedures of the gasserian ganglion (trigeminal ganglion) for the treatment of trigeminal neuralgia. The evoked responses will be measured at two locations before and after the clinical rhizotomy including: the standard contralateral scalp (EEG) and at the gasserian ganglion through an FDA-approved recording electrode.",[30],[30],{"date":294,"type":35},"2025-11-19",{"date":296,"type":35},"2022-04-04",{"date":298,"type":23},"2027-04-07",{"name":258,"class":66},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":43},"100609589","post-operative-trigeminal-pain-after-microvascular-decompression-for-trigeminal-neuralgia-100609589","NCT07216547","Post-Operative Trigeminal Pain After Microvascular Decompression for Trigeminal Neuralgia","Inclusion Criteria:\n\n* MVD post-operative patients with type I Trigeminal Neuralgia.\n\nExclusion Criteria:\n\n* Atypical (Type II) Facial Pain at presentation, revision surgery.\n* Patients who are unable or unwilling to provide informed consent will be excluded from the study.",{"count":307,"type":23},100,"The goal of this observational study is to learn about the long-term effects of microvascular decompression (MVD) in patients with trigeminal neuralgia (TN). The main question it aims to answer is:\n\nDoes undergoing post-operative dental treatment or other orofacial stimulation increase the likelihood of pain relapse after MVD for TN?\n\nParticipants who have previously undergone MVD for TN as part of their standard medical care will be asked to complete surveys over phone call. These surveys will focus on their pain experiences, timing, anxiety attacks and nature of any pain relapses, and whether they have received dental treatments or other orofacial interventions during follow-up.",[30,310,311],"Microvascular Decompression Surgery","Post-operative Pain",[313],"post operative relapse","2025-10-10",{"date":316,"type":35},"2025-10-14",{"date":318,"type":23},"2025-12-12",{"date":320,"type":23},"2026-06-01",{"name":322,"class":66},"Rutgers, The State University of New Jersey",{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":330,"targetDuration":332,"studyType":77,"phases":4,"briefSummary":333,"conditions":334,"keywords":340,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":362},"100603323","prospective-register-study-to-assess-eligibility-for-and-efficacy-of-surgical-treatment-in-patients-with-neurovascular-conflict-100603323","NCT07135024","Prospective Register Study to Assess Eligibility for and Efficacy of Surgical Treatment in Patients With nEuRovascular Conflict","PETER registry","Inclusion Criteria:\n\n* suspected neurovascular conflict\n* signed consent for further use of routine clinical data as accepted by local regulations\n\nExclusion Criteria:\n\n* refusal of further use of routine clinical data",{"count":331,"type":23},5001,"5 Years","The aim of the registry is a multicenter, prospective long-term data collection of patients suspected neurovascular conflict and referred for possible microvascular decompression (Jannetta procedure). The registry relies exclusively on routinely collected clinical data, which are gathered in a standardized and privacy-compliant manner as part of everyday clinical practice. By systematically compiling this information across multiple centers, valuable insights into the effectiveness, potential side effects, and long-term outcomes of this surgical treatment can be gained. The registry will serve as a foundation for future scientific analyses and is intended to help answer relevant research questions regarding the treatment of trigeminal neuralgia based on solid evidence.",[30,335,336,337,338,339],"Tic Douloureux","Facial Pain","Glossopharyngeal Neuralgia","Hemifacial Spasm","Neurovascular Conflict",[30,341,342,343,344,345,346,347,348,349,350,351,352],"Registry","prospective study","eligibility determination","efficacy, treatment","Follow-Up Studies","indication","microvascular decompression","Jannetta","tic douloureux","hemifacial spasm","neurovascular conflict","glossopharyngeal neuralgia","2025-08-13",{"date":355,"type":35},"2025-08-21",{"date":357,"type":23},"2025-10-01",{"date":359,"type":23},"2033-10-01",{"name":361,"class":66},"Gerrit A Schubert",2,{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":24,"phases":372,"briefSummary":373,"conditions":374,"keywords":377,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":386,"locationsCount":43},"100538425","clinical-trial-of-the-safety-and-efficacy-of-peripheral-nerve-stimulation-in-the-treatment-of-peripheral-neuropathic-pain-100538425","NCT06290661","Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain.","Prospective, Multicentre, Randomised Withdrawal Design of a Clinical Trial Evaluating the Safety and Efficacy of a Percutaneous Peripheral Nerve Stimulation System for Patients With Peripheral Neuropathic Pain.","Inclusion criteria:\n\n* 18 years old and above, male or female\n* Diagnosed by trained clinical doctors as postherpetic neuralgia, which is an indication for peripheral nerve stimulation therapy;\n* Assess the damage or disease of the peripheral sensory system through the four questions of Douleur Neuropathy before surgery;\n* The subject has received conventional treatment but the efficacy is poor, or cannot tolerate the side effects of conventional treatment;\n* Visual analogue scale for pain within 24 hours before surgery ≥ 5;\n* The subjects are able to understand the purpose of this study, have sufficient compliance with the research treatment, and are willing to sign an informed consent form;\n\nExclusion criteria:\n\n* Subjects who need to receive both radio frequency modulation and intrathecal drug infusion treatment simultaneously;\n* Subjects who are known to have cardiac implants (pacemakers or defibrillators) or other implantable neural stimulators (spinal cord stimulators or deep brain stimulators, etc.);\n* Subjects with severe psychological and\u002For mental disorders and\u002For non therapeutic drug dependence;\n* Subjects expected to undergo MRI examination within 30 days after PNS implantation;\n* Expected to be discharged within 48 hours or less;\n* Target nerve damage or muscle defects in known pain areas;\n* Subjects who are known to be allergic to skin contact materials (tape or adhesive);\n* Allergy to anesthetics such as lidocaine;\n* Concomitant severe heart disease, liver disease, kidney disease, respiratory system disease, and coagulation dysfunction;\n* Pregnant women, lactating women, or women planning to have children within the next three months;\n* Subjects who have participated in any other clinical trial, or who may participate in any other trial after enrollment;\n* Other situations that the researcher deems unsuitable for participation in this clinical trial",{"count":371,"type":23},60,[54],"The goal of this clinical trial is to evaluate safety and efficacy of percutaneous peripheral nerve stimulation in patients with peripheral neuropathic pain. The main questions it aims to answer are:\n\n1. The efficacy of percutaneous peripheral nerve stimulation in patients with peripheral neuropathic pain\n2. The safety of percutaneous peripheral nerve stimulation in patients with peripheral neuropathic pain Participants are going to undergo procedure that implant peripheral nerve stimulation electrode produced by Jiangsu CED Medtech Co., Ltd. Then the subjects, whose VAS scores decrease more 30% than baseline level, are classified into two groups randomly. One of the group receiving active stimulation called trial group and another receiving placebo stimulation called control group. All subjects are required to make their own subjects' pain diary to record VSA score before and after implantation until at the end of follow-up. Also, participants are asked to report use of analgesic medications, number of awakenings and adverse events.\n\nResearchers will compare pain scores between the two groups to see if peripheral nerve stimulation is effective to patients with peripheral neuropathic pain.",[375,376,30],"Postherpetic Neuralgia","Peripheral Neuropathic Pain",[378,379],"Peripheral Nerve Stimulation","peripheral neuropathic pain","2025-07-22",{"date":382,"type":35},"2025-07-28",{"date":384,"type":35},"2023-02-09",{"date":63,"type":23},{"name":387,"class":66},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":220,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":396,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":405,"leadSponsor":406,"locationsCount":4},"100598674","the-synergism-and-attenuation-effects-of-electroacupuncture-in-the-treatment-of-trigeminal-neuralgia-100598674","NCT07074561","The Synergism and Attenuation Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia","The Synergism and Attenuation Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia：Protocol for a Multicentre Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be eligible for this study:\n\n  1. Met the diagnostic criteria for trigeminal neuralgia (TN) as defined in the International Classification of Headache Disorders, 3rd edition (ICHD-3) published by the International Headache Society (IHS) in 2018.\n  2. Between 18 and 75 years old (inclusive), regardless of gender;\n  3. Currently prescribed carbamazepine (400-800 mg\u002Fday) or oxcarbazepine (800-1600 mg\u002Fday);\n  4. Conscious, alert, and capable of perceiving\u002Fdifferentiating pain, with basic communication abilities;\n  5. Signed informed consent form and voluntary participation in the study.\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria were excluded:\n\n  1. Patients with epilepsy, head injury, or other relevant neurological disorders;\n  2. Patients with severe cardiac, hepatic, or renal impairment;\n  3. Patients with cognitive dysfunction, aphasia, psychiatric disorders, or those unable to cooperate with treatment;\n  4. Patients with poorly controlled hypertension or hyperglycemia;\n  5. Patients with a recent diagnosis of severe anxiety or depression;\n  6. Pregnant or breastfeeding patients;\n  7. Patients with pacemakers or other contraindications to electroacupuncture;\n  8. Patients concurrently enrolled in other clinical studies.",{"count":201,"type":23},[54],"Trigeminal neuralgia (TN), characterized by its refractory nature and recurrence, frequently leads to anxiety, depression, and insomnia, thereby significantly diminishing patients' quality of life and potentially inducing self-harm. Carbamazepine (CBZ) is the first-line medication for TN, yet it presents adverse effects such as addiction and the absence of analgesic effects upon cessation. Acupuncture, particularly electroacupuncture（EA）, has demonstrated efficacy in TN treatment, although its therapeutic outcomes are influenced by various factors. This multicenter, randomized controlled trial aims to evaluate the synergistic efficacy-enhancing and toxicity-reducing effects of the optimized protocol when combined with carbamazepine (CBZ) in treating trigeminal neuralgia (TN), thereby proposing novel therapeutic refinements for electroacupuncture treatment regimens in TN management.",[30],[127,400],"Carbamazepine","2025-07-10",{"date":403,"type":35},"2025-07-20",{"date":403,"type":23},{"date":230,"type":23},{"name":137,"class":66},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":24,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":43},"100532465","a-study-to-investigate-the-efficacy-of-pain-reduction-with-cryoneurolysis-compared-with-sham-treatment-in-adults-with-trigeminal-neuralgia-100532465","NCT06213155","A Study to Investigate the Efficacy of Pain Reduction With Cryoneurolysis Compared With Sham-treatment in Adults With Trigeminal Neuralgia","A Randomized, Parallel Arm, Sham-controlled, Double-blinded, Investigator-initiated Trial to Investigate the Safety and Efficacy of Percutaneous Peripheral Cryoneurolysis Therapy in Medically Refractory Trigeminal Neuralgia: a Pilot Study","CryoGem","Inclusion Criteria:\n\n1. Participant must be 18 years at the time of signing the informed consent\n2. A diagnosis of primary (classic and idiopathic) trigeminal neuralgia affecting the mandibular and\u002For maxillary division, verified by a neurologist\n3. Ability to subclassify the trigeminal neuralgia according to the The International Classification of Headache Disorders, 3rd edition, i.e. sufficient magnetic resonance (MR) evaluation is mandatory\n4. History of minimum mean of three trigeminal neuralgia related pain paroxysms per day last 4 weeks\n5. History of minimum average daily pain intensity NRS score (ADP) of 4 to10 last 4 weeks\n6. In baseline minimum average daily pain intensity NRS score (ADP) of 4 to 10\n7. In baseline minimum mean of three trigeminal neuralgia related pain paroxysms per day\n8. Treatment refractory as defined in this study as failure to respond, pending an adequate trial in the opinion of the investigator, contraindications or intractable side effect to one of two medications:\n\n   1. Carbamazepine\n   2. Oxcarbazepine\n9. Unaltered prophylactic TN medication regime 2 weeks prior to baseline, and be willing to keep regime unaltered during the baseline and the blinded study period.\n10. Be an appropriate candidate for the study intervention required in this study on the basis of the clinical judgment of the investigator\n11. Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\n1. Diagnosed with demyelinating inflammatory disorders such as e.g. multiple sclerosis.\n2. Other pain conditions, not intended to be treated in this study, that in the opinion of the investigator could interfere with study procedures, accurate pain reporting, and\u002For confound evaluation of study endpoints.\n3. High probability of neurological deterioration due to other medical conditions, that in the opinion of the investigator may confound outcome assessment.\n4. Patients exhibiting a high degree of comorbidity and\u002For frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.\n5. Other coexisting current medical conditions, including, but not limited to, bleeding diathesis and thrombophilia, that presents excess procedural risk, in the opinion of the investigator.\n6. Have within 6 months of enrollment a significant untreated addiction to dependency- producing medications, alcohol, or illicit drugs.\n7. Abnormal pain behavior, inappropriate medication use and\u002For unresolved psychiatric illness, that in the opinion of the investigator are significant enough to impact perception of pain, compliance with intervention and\u002For ability to evaluate treatment outcome.\n8. Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the Gasserian ganglion.\n9. Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of a division or branch of the trigeminal nerve being targeted in this study.\n10. Facial anomaly or trauma which renders the planned procedure difficult.\n11. Subject currently has an active oral or dental abscess or a local infection at the site of injection based on present symptoms.\n12. Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past 6 months.\n13. Current participation in another treatment study\n14. Sensory deficits and\u002For pain configuration supporting, in the opinion of the neurologist, trigeminal neuropathy as more likely diagnosis.\n15. Patients with any kind of conductive implant with contraindication for nerve stimulation according to study innervation.",{"count":22,"type":23},[54],"The CryoGem Trial is a research study that tests a freezing technique called cryoneurolysis to see if it helps relieve pain in adults with trigeminal neuralgia. Trigeminal neuralgia is a condition that causes severe facial pain. In this study, we want to find out if the freezing technique is effective and safe. We will do this by comparing two groups of adults with trigeminal neuralgia. One group will receive the actual treatment, while the other group will receive a fake treatment called a sham. Neither the participants nor the assessors will know which group they are in (this is called a blinded study). For the next four weeks, participants in both groups will continue recording their headaches without knowing which treatment they are receiving. After this initial period, there will be an extension period where all participants can receive treatment as needed for up to two years. The results of this study will help us decide if the freezing technique is a viable treatment option for trigeminal neuralgia. Our main goal is to see how many people in each group have a significant reduction in pain (at least 75% less pain). We will also record other important information about the participants.\n\nWe are looking to recruit up to 24 adults with trigeminal neuralgia to take part in this study. All participants will keep a daily diary for two weeks to track their headaches before starting the treatment. Then, they will be randomly assigned to either the treatment group or the sham group.",[30],"2025-06-18",{"date":421,"type":35},"2025-06-19",{"date":423,"type":35},"2024-02-29",{"date":425,"type":23},"2026-12",{"name":427,"class":66},"St. Olavs Hospital",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":448,"locationsCount":43},"100443182","assessment-in-patients-with-essential-trigeminal-neuralgia-of-nerve-involvement-by-mri-in-dti-and-functional-connectivity-in-resting-state-100443182","NCT05051072","Assessment in Patients With Essential Trigeminal Neuralgia of Nerve Involvement by MRI in DTI and Functional Connectivity in \"Resting State\"","SENSE","Inclusion Criteria:\n\n* Adult patients (18 years and over);\n* Supported in the neurosurgery department or at the assessment and treatment center for pain for unilateral essential trigeminal neuralgia with search for vasculo-nervous conflict;\n\nExclusion Criteria:\n\n* Patient with neurodegenerative or inflammatory neurological pathology;\n* Patient who has already been operated on for a DMV;\n* Absolute contraindication to MRI\n* Patient benefiting from a legal protection measure; with impaired judgment skills or unable to receive information;\n* Pregnant or breastfeeding women",{"count":371,"type":23},[54],"Essential trigeminal neuralgia is the most common facial pain. In forms resistant to drug and disabling treatments, surgical treatment may be offered to the patient. The type of intervention will be conditioned by the presence or absence of a vasculo-nervous conflict objectified by MRI(Magnetic resonance imaging) Morphological MRI with contrast injection does not always allow an accurate assessment of trigeminal nerve damage in patients with essential facial neuralgia. Despite advances in the anatomical definition of high-resolution MRI, the correlation between a vascular conflict visible on MRI and present during surgery and prolonged postoperative clinical improvement remains insufficient These data raise the question of additional imaging sequences to assess the distressing characteristics of NT in addition to the usual anatomical criteria for compression By performing during morphological MRI two additional sequences, one in diffusion tensor (DTI) and one in resting state (fMRI), we could better characterize the achievement of NT\n\nThe contribution of new imaging sequences in the context of essential trigeminal neuralgia treated with microvascular decompression (MVD) would:\n\n1\u002Fimprove the diagnostic criteria for suffering and compression of the NT (trigeminal nerve) 2 \u002F define objective prognostic criteria for the effectiveness of surgery, particularly in the context of unusual clinical symptoms or moderate conflict on MRI (Magnetic resonance imaging) 3 \u002F to analyze more precisely the causes of recurrence at a distance from surgery and help in the decision of re-intervention Our main hypothesis: the addition of a diffusion tensor sequence and sequences (allowing functional brain analysis) in addition to standard anatomical MRI in the assessment of a vasculo-nervous conflict would allow us to better characterize involvement of the trigeminal nerve in essential facial neuralgia. It also helps guide therapeutic management and surgical indications.\n\nThis is a prospective, monocentric cohort study. It will be offered to patients referred to neurosurgery or to the pain assessment and treatment center for assessment and management of a neuralgia of the essential trijumeau unilateral.",[30,310,439],"Diffusion Tensor Imaging",[441],"Resting state","2025-06-06",{"date":444,"type":35},"2025-06-11",{"date":446,"type":35},"2022-04-27",{"date":110,"type":23},{"name":449,"class":450},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":459,"maxAge":20,"enrollmentInfo":460,"targetDuration":4,"studyType":24,"phases":461,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":43},"100593981","comparison-of-two-types-of-radiofrequency-treatment-for-trigeminal-neuralgia-100593981","NCT07013500","Comparison of Two Types of Radiofrequency Treatment for Trigeminal Neuralgia","Comparison of Gasserian Ganglion Conventional Radiofrequency and Peripheral Pulsed Radiofrequency in Trigeminal Neuralgia","TN-RFA-MEU25","Inclusion Criteria:\n\n* Patients aged between 55 and 80 years with a diagnosis of classical trigeminal neuralgia according to the International Classification of Headache Disorders, 3rd edition (ICHD-3). Patients must have experienced pain refractory to medical management for at least 6 months and have complete clinical and procedural records available, including follow-up data for a minimum of 6 months.\n\nExclusion Criteria:\n\n* Patients with secondary trigeminal neuralgia due to structural causes such as multiple sclerosis or tumors, those with a history of prior craniofacial surgery or neuroablative procedures, patients lacking sufficient follow-up data, and those with contraindications to sedation or with uncontrolled systemic comorbidities are excluded from the study.","55 Years",{"count":371,"type":23},[54],"Trigeminal neuralgia (TN) is a chronic pain condition that affects the face, often causing sharp, electric shock-like pain in areas served by the trigeminal nerve. When medications are no longer effective, interventional procedures such as radiofrequency ablation (RFA) may be used. This retrospective study compares two different RFA techniques in patients with classical TN: (1) conventional thermal RFA applied to the Gasserian ganglion, and (2) pulsed RFA applied peripherally to the nerve branches.\n\nThe purpose of the study is to evaluate pain relief, patient satisfaction, and complication rates between these two commonly used techniques. A total of 60 patients aged 55-80 years, who were treated at the Mersin University Pain Clinic between January 2015 and June 2025, were included. The study uses clinical records and follow-up data to assess outcomes at 6 months post-procedure.\n\nThis study aims to provide clinicians with more evidence to guide the selection of safer and more effective treatments for trigeminal neuralgia, with the goal of improving patients' quality of life and reducing treatment-related side effects.",[30,335,464],"Neuropathic Facial Pain",[30,466,467,468,93],"Radiofrequency Ablation","Pulsed Radiofrequency","Gasserian Ganglion","2025-06-02",{"date":471,"type":35},"2025-06-10",{"date":473,"type":23},"2025-06-15",{"date":475,"type":23},"2025-07-30",{"name":477,"class":66},"Mesut Bakır",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":486,"conditions":487,"keywords":488,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":43},"100581561","intravenous-lacosamide-for-the-treatment-of-acute-pain-in-trigeminal-neuralgia-100581561","NCT06851910","Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia","Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia: A Prospective Observational Study","All patients diagnosed with trigeminal neuralgia who present to the emergency department of Hospital de Bellvitge for an acute pain exacerbation and are prescribed intravenous lacosamide as symptomatic pain treatment, according to the treating physician's discretion, will be considered for inclusion.\n\nInclusion Criteria:\n\n* Diagnosis of classical or idiopathic trigeminal neuralgia according to the criteria of the International Classification of Headache Disorders (ICHD-3).\n* Age over 18 years.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Contraindication for treatment with lacosamide (previous hypersensitivity reaction, known atrioventricular block).\n* Mental or psychiatric illness that interferes with the ability to understand and sign the informed consent.\n* Language barrier.\n* Lack of cooperation.",{"count":173,"type":23},"This prospective observational study evaluates the effectiveness and safety of intravenous lacosamide as a rescue treatment for acute pain in patients presenting to the emergency department with trigeminal neuralgia",[30],[181,489,490,491],"lacosamide","acute treatment","rescue treatment","2025-04-27",{"date":494,"type":35},"2025-04-29",{"date":496,"type":35},"2025-04-21",{"date":498,"type":23},"2027-05",{"name":500,"class":66},"Hospital Universitari de Bellvitge",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":24,"phases":509,"briefSummary":510,"conditions":511,"keywords":513,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":43},"100450966","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-stem-cells-exosomes-for-trigeminal-neuralgia-100450966","NCT05152368","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells Exosomes for Trigeminal Neuralgia","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells Exosomes for the Treatment of Trigeminal Neuralgia","Inclusion Criteria:\n\n* Diagnosis of Trigeminal Neuralgia or Peripheral Neuropathy\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":173,"type":23},[26],"This trial will study the safety and efficacy of instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Trigeminal Neuralgia.",[512,30],"Peripheral Neuropathy",[512,30,514],"stem cell treatment","2025-04-15",{"date":517,"type":35},"2025-04-17",{"date":519,"type":35},"2022-09-09",{"date":521,"type":23},"2026-01",{"name":523,"class":66},"The Foundation for Orthopaedics and Regenerative Medicine",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":531,"maxAge":532,"enrollmentInfo":533,"targetDuration":4,"studyType":24,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":43},"100537466","masseter-muscle-thickness-in-gasser-ganglion-radiofrequency-treatment-100537466","NCT06278194","Masseter Muscle Thickness in Gasser Ganglion Radiofrequency Treatment","Change of the Masseter Muscle Thickness Measured by Ultrasonography After Gasser Ganglion Radiofrequency Thermocoagulation Treatment","Inclusion Criteria:\n\n* Pain refractory to medical therapy for at least 3 months\n* Planning radiofrequency thermocoagulation of gasserian ganglion\n* Accept ultrasound measurements to be performed\n\nExclusion Criteria:\n\n* Refused to participate in the study\n* Not attending follow-ups regularly\n* Coagulation disorder\n* Pregnancy\n* Localized or systemic infection","40 Years","85 Years",{"count":244,"type":23},[54],"Trigeminal neuralgia is common painful disorder in pain medicine clinics. Gasserian ganglion radiofrequency thermocoagulation is one of the treatment option in patients with trigeminal neuralgia in refractory cases. The most commonly involved branch in trigeminal neuralgia is the mandibular branch. Masseter muscle is innervated by mandibulary nerve branch of the trigeminal nerve.\n\nThe radiofrequency thermocoagulation therapy is used to ablate the affected trigeminal nerve branch and some of patients complain of subjective masseter weakness after this procedure.\n\nIn theoretical basis, muscles innervated by target nerve are affected from ablation procedure. In this study the primary aim is to evaluate the change of the masseter muscle thickness in patients treated by gasserian ganglion radiofrequency thermocoagulation. The results may also show possible functional effect of the procedure related with masseter muscle.",[30,537],"Gasserian Ganglion; Lesion","2025-03-03",{"date":540,"type":35},"2025-03-05",{"date":542,"type":35},"2024-03-15",{"date":544,"type":23},"2025-10-15",{"name":546,"class":547},"Başakşehir Çam & Sakura City Hospital","OTHER_GOV",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":555,"targetDuration":557,"studyType":77,"phases":4,"briefSummary":558,"conditions":559,"keywords":560,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":43},"100491293","observational-study-on-the-treatment-of-trigeminal-neuralgia-by-radiosurgery-100491293","NCT05677243","Observational Study on the Treatment of Trigeminal Neuralgia by Radiosurgery","NATURE","Inclusion Criteria:\n\n* Classical trigeminal neuralgia according the International Classification of Headache Disorders\n* Trigeminal neuralgia resistant to the maximum tolerated medical therapy, with pain intensity according to the Barrow Neurological Institute (BNI) score IV or V.\n* Patients aged \\> 18\n\nExclusion Criteria:\n\n* Patients suffering from secondary Trigeminal neuralgia (tumour in the cerebellopontine angle, arteriovenous malformation or multiple sclerosis)\n* Previous history of radiosurgery procedure",{"count":556,"type":23},150,"10 Years","This study aims to evaluate the outcome of patient treated by radiosurgery on LINAC with high dose rate for classical trigeminal neuralgia",[30],[30,561,562,563,564],"Radiosurgery","LINAC","Pain relief","Hypesthesia","2025-02-17",{"date":567,"type":35},"2025-02-19",{"date":569,"type":35},"2021-12-15",{"date":571,"type":23},"2036-12",{"name":573,"class":66},"Centre Hospitalier Princesse Grace",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":24,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":362},"100575999","fluoroscopic-guided-bipolar-versus-monopolar-pulsed-radiofrequency-for-refractory-trigeminal-neuralgia-100575999","NCT06779578","Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia","The Efficacy and Safety of Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia: An Exploratory Study","Inclusion Criteria:\n\n1. Patients with a definitive diagnosis of classical TN based on the third version of the International Classification of Headache Disorders (ICHD-3).\n2. Either purely paroxysmal classical TN or classical TN with concomitant chronic pain.\n3. Patients with idiopathic TN, with symptomatic clinical topography of V2 and\u002For V3.\n4. Patients with brain magnetic resonance imaging (MRI) unremarkable for structural etiology for the trigeminal pain.\n5. Patients with medically refractory TN defined as pain persisting beyond three months at a level of ≥5\u002F10 after monotherapy or polytherapy in appropriate medical doses.\n\nExclusion Criteria:\n\n1. Painful trigeminal neuropathy based on the third version of the International Classification of Headache Disorders (ICHD-3).\n2. Trigeminal neuralgia with V1 symptomatic clinical topography.\n3. Trigeminal neuralgia comorbid with other atypical facial pain disorders.\n4. Structural TN e.g., due to vascular compression, posterior fossa tumors, central demyelination, …etc.\n5. Patients exposed to previous radiofrequency procedures, as this may impair the nerve response to current PRF.\n6. Patients who refused to participate in the study.",{"count":173,"type":23},[54],"A prospective exploratory study aiming at comparing pulsed bipolar versus pulsed unipolar radiofrequency ablation in patients with medically refractory trigeminal neuralgia.",[30,585],"Refractory Pain",[181,587,588,589,590],"Radiofrequency ablation","Pulsed radiofrequency","Monopolar pulsed radiofrequency","Bipolar pulsed radiofrequnency","2025-01-16",{"date":593,"type":35},"2025-01-17",{"date":595,"type":35},"2024-01-01",{"date":597,"type":23},"2025-09-01",{"name":65,"class":66},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":24,"phases":608,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":43},"100568672","comparison-of-pulsed-and-thermal-radiofrequency-for-trigeminal-neuralgia-100568672","NCT06684275","Comparison of Pulsed and Thermal Radiofrequency for Trigeminal Neuralgia","Comparison of Pulsed and Thermal Radiofrequency for the Treatment of Trigeminal Neuralgia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18-60 years.\n* Diagnosis of classical trigeminal neuralgia, as per the International Classification of Headache Disorders criteria\n* Patients experiencing unilateral, episodic facial pain for at least six months with a Numeric Rating Scale (NRS) score greater than 6, despite medical treatment.\n* Able to provide informed consent.\n* Agree to follow the study procedures and attend follow-up visits.\n\nExclusion Criteria:\n\n* Patients with secondary trigeminal neuralgia (e.g., due to tumors, multiple sclerosis).\n* Previous surgery or radiofrequency treatment for trigeminal neuralgia.\n* Pregnant or breastfeeding women.\n* Known allergies to anesthetics or other agents used in the procedure.\n* Significant psychiatric disorders that may interfere with pain assessment or study participation.\n* Coagulopathy or use of anticoagulants that contraindicate the procedure.","60 Years",{"count":371,"type":23},[54],"The goal of this clinical trial is to compare the effectiveness of Pulsed Radiofrequency (PRF) with Pulsed and Thermal Radiofrequency (PRF + TRF) in treating Trigeminal Neuralgia (TN) in adults.\n\nThe main questions it aims to answer are:\n\n* Does PRF or PRF + TRF provide better pain relief for patients with trigeminal neuralgia?\n* What is the safety profile and complication rate of PRF versus PRF + TRF?\n\nResearchers will compare the effects of PRF and PRF + TRF to see if thermal lesioning in addition to pulsed RF provides superior long-term pain relief and reduces the need for analgesic medication.\n\nParticipants will:\n\n* Undergo either PRF or PRF + TRF treatment targeting the trigeminal nerve.\n* Be assessed for pain relief, functional status, and adverse events over a 3-month follow-up period.",[30],[30,467,612,93,336,466],"Thermal Radiofrequency","2024-12-29",{"date":615,"type":35},"2024-12-31",{"date":617,"type":35},"2024-11-10",{"date":619,"type":23},"2025-04-10",{"name":621,"class":547},"Zagazig University",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":4,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":629,"targetDuration":4,"studyType":24,"phases":631,"briefSummary":632,"conditions":633,"keywords":634,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":43},"100473927","phase-1-deep-brain-stimulation-for-refractory-trigeminal-neuralgia-with-a-pontine-lesion-100473927","NCT05451251","Deep Brain Stimulation for Refractory Trigeminal Neuralgia with a Pontine Lesion","Deep Brain Stimulation for Refractory Trigeminal Neuralgia with a Pontine Lesion: a Pilot Study","Inclusion Criteria:\n\n* Adults of at least 18 years old\n* Refractory trigeminal neuralgia : failure of at least 3 drugs and at least two lesioning surgical interventions (radiosurgery, percutaneous rhizotomy, or open rhizotomy).\n* Pontine lesion proved by MRI in contact with trigeminal nerve tract\n\nExclusion Criteria:\n\n* Absolute contraindication to MRI\n* Medical contraindication to the procedure",{"count":630,"type":23},6,[26],"The aim of this study is to assess the feasibility of deep brain stimulation for refractory trigeminal neuralgia due to a pontine lesion, as is usually seen in the context of multiple sclerosis.\n\nThese patients usually have severe intractable facial pain and current medical and surgical options generally fail to achieve long lasting pain relief.\n\nHoping to improve pain control in this population, the investigators of this trial propose a novel technique consisting of implanting a deep brain stimulation lead within the pontine lesion to modulate the generation of pain signals.",[30],[635,636,637],"Multiple sclerosis","Deep brain stimulation","Pontine lesion","2024-12-06",{"date":640,"type":35},"2024-12-12",{"date":642,"type":35},"2024-10-15",{"date":644,"type":23},"2026-10",{"name":646,"class":66},"Université de Sherbrooke"]